Letters to the Editor
29 April 2020

Antirheumatic in SARS-CoV-2: benefit or risk?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1881
Views
545
Downloads
6
HTML

Authors

Not available

Altmetrics

Downloads

Download data is not yet available.

Citations

How to Cite



Antirheumatic in SARS-CoV-2: benefit or risk?. (2020). Italian Journal of Medicine, 14(2), 114-115. https://doi.org/10.4081/itjm.2020.1290

Similar Articles

1-10 of 611

You may also start an advanced similarity search for this article.